HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT02281773

A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

Medication studyAges 18–55Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations
Little Rock and 42 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study clarity

Study information

Study start dateStarted: November 10, 2014
Recruitment status
Completed
Enrollment listed in the registry
518
Sponsor
Boehringer Ingelheim
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Canada, Germany, ...
Age range
From 18 Years to 55 Years
Official registry ID
NCT02281773
Official title
Show the full official title

A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Little Rock, United States · Cerritos, United States · Garden Grove, United States

37 more locations
  • Los Angeles, United States
  • National City, United States
  • Orange, United States
  • San Diego, United States
  • Torrance, United States
  • Washington D.C., United States
  • Lauderhill, United States
  • Maitland, United States
  • North Miami, United States
  • Atlanta, United States
  • Chicago, United States
  • Lake Charles, United States
  • St Louis, United States
  • Cedarhurst, United States
  • Rochester, United States
  • Staten Island, United States
  • Austin, United States
  • DeSoto, United States
  • Penticton, Canada
  • Burlington, Canada
  • Cologne, Germany
  • Düsseldorf, Germany
  • Heidelberg, Germany
  • Aichi, Toyoake, Japan
  • Hokkaido, Sapporo, Japan
  • Hyogo, Kobe, Japan
  • Nara, Kashihara, Japan
  • Osaka, Moriguchi-city, Japan
  • Saga, Kanzaki-gun, Japan
  • Tokushima, Anan, Japan
  • Tokyo, Kodaira, Japan
  • Tokyo, Setagaya, Japan
  • Tokyo, Shinagawa, Japan
  • Changhua, Taiwan
  • Kaohsiung City, Taiwan
  • Tainan, Taiwan
  • Taipei, Taiwan
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Boehringer Ingelheim.

Did this study involve medication?

Yes. The study involved medication, including BI 409306 100 mg QD, BI 498306 50 mg QD, Placebo, BI 498306 25 mg QD and BI 409306 10 mg QD.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies